Institution
University of Paris
Education•Paris, France•
About: University of Paris is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Transplantation. The organization has 102426 authors who have published 174180 publications receiving 5041753 citations. The organization is also known as: Sorbonne.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this article, the authors argue that interpersonal exchanges of resources between R&D scientists across organizational boundaries can represent intellectual capital leaks, and they propose a grounded theoretical framework to identify such leaks.
Abstract: Though key to fostering innovation, interpersonal exchanges of resources between R&D scientists across organizational boundaries can represent intellectual capital leaks. A grounded theoretical fra...
658 citations
TL;DR: An algorithm based on bidimensional empirical mode decomposition (BEMD) to extract features at multiple scales or spatial frequencies to apply to texture extraction and image filtering, which are widely recognized as a difficult and challenging computer vision problem.
658 citations
Sahlgrenska University Hospital1, National Institutes of Health2, University of Paris3, Children's Hospital Oakland Research Institute4, University of Glasgow5, Centro Nacional de Investigaciones Cardiovasculares6, Aarhus University7, Medical University of Vienna8, University of Amsterdam9, University of California, Los Angeles10, University of Western Ontario11, Monash University12, University of Copenhagen13, University of Western Australia14, Royal Perth Hospital15, French Institute of Health and Medical Research16, Oregon Health & Science University17, University of Cambridge18, University of Bristol19, Trinity College, Dublin20, University of Texas Southwestern Medical Center21, Charité22, Utrecht University23, University of the Witwatersrand24, Imperial College London25, Technische Universität München26, University of Helsinki27, University of Groningen28, Hacettepe University29, University of Milan30, Columbia University31
TL;DR: In this paper, the authors proposed a method to solve the problem of the problem: this paper ] of "uniformity" of the distribution of data points in the data set.
Abstract: Abstract
655 citations
University of Michigan1, National University of Singapore2, University of Toronto3, Utah System of Higher Education4, Boston Children's Hospital5, Medical City Dallas Hospital6, Extracorporeal Life Support Organization7, Baylor College of Medicine8, NewYork–Presbyterian Hospital9, Central Texas College10, University of Paris11
TL;DR: In patients with COVID-19 who received ECMO, both estimated mortality 90 days after ECMO and mortality in those with a final disposition of death or hospital discharge were less than 40%.
655 citations
TL;DR: Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation and decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources.
Abstract: Background Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV-positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P<0.001) and the seropositive patients (P=0.03). Among the seronegative patients, the incidence of CMV disease 90 days after transplantation was 45 percent among placebo recipients and 3 percent among valacyclovir recipients. Among the seropositive patients, the respective values were 6 percent and 0 percent. At six months, the incidence of CMV disease was 45 percent among seronegative recipients of placebo and 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placebo recipients and 1 percent among seropositive valacyclovir recipients. At six months, the rate of biopsy-confirmed acute graft rejection in the seronegative group was 52 percent among placebo recipients and 26 percent among valacyclovir recipients (P=0.001). Treatment with valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources. Hallucinations and confusion were more common with valacyclovir treatment, but these events were not severe or treatment limiting. The rates of other adverse events were similar among the groups. Conclusions Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation. (N Engl J Med 1999; 340:1462-70.) (C) 1999, Massachusetts Medical Society.
654 citations
Authors
Showing all 102613 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Guido Kroemer | 236 | 1404 | 246571 |
| David H. Weinberg | 183 | 700 | 171424 |
| Paul M. Thompson | 183 | 2271 | 146736 |
| Chris Sander | 178 | 713 | 233287 |
| Sophie Henrot-Versille | 171 | 957 | 157040 |
| Richard H. Friend | 169 | 1182 | 140032 |
| George P. Chrousos | 169 | 1612 | 120752 |
| Mika Kivimäki | 166 | 1515 | 141468 |
| Martin Karplus | 163 | 831 | 138492 |
| William J. Sandborn | 162 | 1317 | 108564 |
| Darien Wood | 160 | 2174 | 136596 |
| Monique M.B. Breteler | 159 | 546 | 93762 |
| Paul Emery | 158 | 1314 | 121293 |
| Wolfgang Wagner | 156 | 2342 | 123391 |
| Joao Seixas | 153 | 1538 | 115070 |